Compare PRA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | VCEL |
|---|---|---|
| Founded | 1976 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.7B |
| IPO Year | 2000 | 1996 |
| Metric | PRA | VCEL |
|---|---|---|
| Price | $24.57 | $29.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $25.00 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 626.4K | 610.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.99 | 0.32 |
| Revenue | ★ $1,098,028,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ $24.98 | $96.31 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $22.72 | $29.24 |
| 52 Week High | $24.85 | $45.97 |
| Indicator | PRA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 30.35 |
| Support Level | $23.88 | N/A |
| Resistance Level | $24.64 | $38.48 |
| Average True Range (ATR) | 0.13 | 1.52 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 34.88 | 9.09 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.